64 related articles for article (PubMed ID: 7612051)
1. Beta 1-adrenoceptor subtype selective antagonism of esmolol and its major metabolite in vitro and in man. Investigations using tricresylphosphate as red blood cell carboxylesterase inhibitor.
Jahn P; Eckrich B; Schneidrowski B; Volz-Zang C; Schulte B; Mutschler E; Palm D
Arzneimittelforschung; 1995 May; 45(5):536-41. PubMed ID: 7612051
[TBL] [Abstract][Full Text] [Related]
2. Esmolol, an ultrashort-acting, selective beta 1-adrenoceptor antagonist: pharmacodynamic and pharmacokinetic properties.
Volz-Zang C; Eckrich B; Jahn P; Schneidrowski B; Schulte B; Palm D
Eur J Clin Pharmacol; 1994; 46(5):399-404. PubMed ID: 7957532
[TBL] [Abstract][Full Text] [Related]
3. Biochemical properties of blood esmolol esterase.
Quon CY; Stampfli HF
Drug Metab Dispos; 1985; 13(4):420-4. PubMed ID: 2863104
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the binding affinity of some newly synthesized phenylethanolamine and phenoxypropanolamine compounds at recombinant human beta- and alpha1-adrenoceptor subtypes.
Ahmed M; Hanaoka Y; Kiso T; Kakita T; Ohtsubo Y; Muramatsu I; Nagatomo T
J Pharm Pharmacol; 2005 Jan; 57(1):75-81. PubMed ID: 15638996
[TBL] [Abstract][Full Text] [Related]
5. Effects of (-)-RO363 at human atrial beta-adrenoceptor subtypes, the human cloned beta 3-adrenoceptor and rodent intestinal beta 3-adrenoceptors.
Molenaar P; Sarsero D; Arch JR; Kelly J; Henson SM; Kaumann AJ
Br J Pharmacol; 1997 Jan; 120(2):165-76. PubMed ID: 9117106
[TBL] [Abstract][Full Text] [Related]
6. Species differences in the stereoselective hydrolysis of esmolol by blood esterases.
Quon CY; Mai K; Patil G; Stampfli HF
Drug Metab Dispos; 1988; 16(3):425-8. PubMed ID: 2900735
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and first in vivo evaluation of new selective high affinity beta1-adrenoceptor radioligands for SPECT based on ICI 89,406.
Wagner S; Kopka K; Law MP; Riemann B; Pike VW; Schober O; Schäfers M
Bioorg Med Chem; 2004 Aug; 12(15):4117-32. PubMed ID: 15246089
[TBL] [Abstract][Full Text] [Related]
8. Kinetics of esmolol, an ultra-short-acting beta blocker, and of its major metabolite.
Sum CY; Yacobi A; Kartzinel R; Stampfli H; Davis CS; Lai CM
Clin Pharmacol Ther; 1983 Oct; 34(4):427-34. PubMed ID: 6617063
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological evaluation of plasma membrane beta-adrenoceptors in rat hearts using the tissue segment binding method.
Horinouchi T; Morishima S; Tanaka T; Suzuki F; Tanaka Y; Koike K; Muramatsu I
Life Sci; 2006 Aug; 79(10):941-8. PubMed ID: 16725159
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous determination of the enantiomers of esmolol and its acid metabolite in human plasma by reversed phase liquid chromatography with solid-phase extraction.
Tang YH; He Y; Yao TW; Zeng S
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Jun; 805(2):249-54. PubMed ID: 15135097
[TBL] [Abstract][Full Text] [Related]
11. Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol.
Horinouchi T; Morishima S; Tanaka T; Suzuki F; Tanaka Y; Koike K; Miwa S; Muramatsu I
Life Sci; 2007 Jul; 81(5):399-404. PubMed ID: 17628611
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of beta-adrenoceptor blocking efficacy of two formulations of esmolol in vivo and in vitro.
Tripathi CB; Bhattacharya P; Bhatt JD; Hemavathi KG
Indian J Physiol Pharmacol; 1999 Apr; 43(2):255-8. PubMed ID: 10365322
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of atracurium in human and rat plasma.
Nigrovic V; Pandya JB; Auen M; Wajskol A
Anesth Analg; 1985 Nov; 64(11):1047-52. PubMed ID: 2932037
[TBL] [Abstract][Full Text] [Related]
14. [Esmolol in anesthesiology: pharmacology and indications].
Fita G; Gomar C; Rovira I
Rev Esp Anestesiol Reanim; 1999 Nov; 46(9):404-14. PubMed ID: 10613078
[TBL] [Abstract][Full Text] [Related]
15. [New ultra-short-acting beta-blockers: landiolol and esmolol--the effects on cardiovascular system].
Mio Y
Masui; 2006 Jul; 55(7):841-8. PubMed ID: 16856544
[TBL] [Abstract][Full Text] [Related]
16. Beta-1 selective adrenergic antagonist landiolol and esmolol can be safely used in patients with airway hyperreactivity.
Yamakage M; Iwasaki S; Jeong SW; Satoh J; Namiki A
Heart Lung; 2009; 38(1):48-55. PubMed ID: 19150530
[TBL] [Abstract][Full Text] [Related]
17. Esterases Involved in the Rapid Bioconversion of Esmolol after Intravenous Injection in Humans.
Imai T; Isozaki M; Ohura K
Biol Pharm Bull; 2022; 45(10):1544-1552. PubMed ID: 36184514
[TBL] [Abstract][Full Text] [Related]
18. Metabolism and urinary excretion of esmolol in humans.
Achari R; Drissel D; Matier WL; Hulse JD
J Clin Pharmacol; 1986 Jan; 26(1):44-7. PubMed ID: 2869058
[TBL] [Abstract][Full Text] [Related]
19. Esmolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
Benfield P; Sorkin EM
Drugs; 1987 Apr; 33(4):392-412. PubMed ID: 2885168
[TBL] [Abstract][Full Text] [Related]
20. Gas chromatographic-mass spectrometric assay for the ultra-short-acting beta-blocker esmolol.
Sum CY; Yacobi A
J Pharm Sci; 1984 Aug; 73(8):1177-9. PubMed ID: 6149299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
